{"id":1068321,"date":"2023-03-31T00:42:43","date_gmt":"2023-03-31T04:42:43","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/gt-biopharma-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update\/"},"modified":"2024-08-18T11:45:52","modified_gmt":"2024-08-18T15:45:52","slug":"gt-biopharma-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/gt-biopharma-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update.php","title":{"rendered":"GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update"},"content":{"rendered":"<p><![CDATA[BRISBANE, CALIFORNIA, March  30, 2023  (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the \u201cCompany\u201d) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE\u00ae platform, today announced fourth quarter and full-year 2022 results for the period ended December 31, 2022.]]><\/p>\n<p>See original here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2023\/03\/30\/2638251\/0\/en\/GT-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update\">GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068321","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068321"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068321"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068321\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}